Sign in to view content

Five-Year Outcomes After Initial Aflibercept, Bevacizumab, or Ranibizumab Treatment for Diabetic Macular Edema (Protocol T)

Dante Joseph Pieramici, MD

Video
Published 2020

Related

Diabetic Retinopathy 3 Symposium
Annual Meeting Talks
2020
Efficacy, Safety, and Durability of Faricimab in Diabetic Macular Edema (DME): One-Year Results From the Phase 3 YOSEMITE and RHINE Trials
Caroline Baumal, MD
Updates from the Field
2021
Efficacy, Durability, and Safety of Faricimab in DME: 2-Year Results From the Phase 3 YOSEMITE and RHINE Trials
Jennifer I. Lim, MD, FARVO, FASRS
Updates from the Field
2022

Category: Diabetic Retinopathy

See more